Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

AbCellera rises on deal with Incyte to develop therapeutic antibodies in oncology

** Shares of biotechnology company AbCellera Biologics 
 ABCL.O  up 1.8% at $5.22
    ** Co enters strategic collaboration with drugmaker Incyte
Corp  INCY.O  to discover and develop therapeutic antibodies in
oncology
    ** Under deal, Incyte has right to develop and commercialize
therapeutic antibodies resulting from collaboration
    ** ABCL to get research payments; also eligible to get
downstream clinical and regulatory milestone payments and
royalties on net sales of products
    ** Including session gains, ABCL stock down ~48.32% YTD  



 (Reporting by Judes Joseph in Bengaluru)
 ((Judes.joseph@thomsonreuters.com))

Recent news on AbCellera Biologics

See all news